Optimisation of quantitative miRNA panels to consolidate the diagnostic surveillance of HBV-related hepatocellular carcinoma

Trung, Ngo Tat; Duong, Dang Chieu; Tong, Hoang Van; Hien, Tran Thi Thu; Hoan, Phan Quoc; Bang, Mai Hong; Binh, Mai Thanh; Ky, Thai Doan; Tung, Nguyen Lam; Thịnh, Nguyễn Tiến; Sang, Vu Viet; Thảo, Lê Thị Phương; Bock, C.‐Thomas; Velavan, Thirumalaisamy P.; Meyer, Christian G.; Song, Lê Hữu; Toàn, Nguyễn Lĩnh

doi:10.1371/journal.pone.0196081

Cited by 16 publications

(21 citation statements)

References 35 publications

(49 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Table S2 included miR‐24, miR‐665, miR‐150, and miR‐296, which have been reported as upregulated in serum from individuals with HCC . However, miR‐122 and miR‐21, which were upregulated in serum from patients with HCC in many reports, were not significantly different between HCC and NC. This was presumably because very limited numbers of samples were available for NC ( n = 2) in this microarray analysis of miRNA, and we used this microarray analysis as the first screening for ETR of HCC.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Circulating microRNA‐1246 as a possible biomarker for early tumor recurrence of hepatocellular carcinoma

Chuma

Toyoda

Matsuzaki³

et al. 2019

Hepatology Research

View full text Add to dashboard Cite

Aims Early tumor recurrence (ETR) after hepatic resection is a crucial predictor of poor prognosis in patients with hepatocellular carcinoma (HCC). The aim of this study was to identify clinically significant serum microRNAs (miRNAs) involved in the ETR of HCC. Methods We compared expression profiles of circulating miRNAs from serum samples between five HCC patients with ETR (recurrence within 12 months after hepatectomy) and five HCC patients without recurrence using microarray analysis of miRNA. The identified miRNA associated with ETR was further verified in 121 HCC patients, 73 liver disease patients, and 15 health controls by real‐time quantitative reverse transcription–polymerase chain reaction (PCR). Results Of the approximately 2000 miRNAs analyzed, we identified 15 miRNAs for which expression levels correlated significantly with ETR. Of these miRNAs, we further investigated expression of miRNA‐1246 (miR‐1246). Quantitative PCR confirmed that miR‐1246 was upregulated in HCC with ETR, compared to the level in HCC without ETR (P < 0.001). Serum miR‐1246 showed a receiver operating characteristic curve area of 0.762, with 77.4% specificity and 54.1% sensitivity in discriminating HCC patients with ETR from HCC patients without ETR. Altered expression of miR‐1246 was associated with aggressive tumor characteristics, including tumor–node–metastasis classification (P = 0.0413), tumor differentiation (P = 0.0419), and portal vein invasion (P = 0.0394). Moreover, multivariate Cox regression analysis identified serum miR‐1246 level as an independent risk factor for overall survival (hazard ratio, 2.784; 95% confidence interval, 1.528–5.071; P = 0.0008). Conclusion Circulating miR‐1246 in serum has strong potential as a novel ETR and prognostic biomarker for HCC.

show abstract

Section: Discussionmentioning

confidence: 99%

“…Concerning plasma/serum miRNAs in HCC, several research groups have reported the potential utility of miRNAs circulating in plasma/serum in clinical applications . However, to date, few reports have described the role of circulating miRNAs in ETR, apart from reports of miRNAs in tissue samples associated with ETR …”

Section: Introductionmentioning

confidence: 99%

Circulating microRNA‐1246 as a possible biomarker for early tumor recurrence of hepatocellular carcinoma

Chuma

Toyoda

Matsuzaki³

et al. 2019

Hepatology Research

View full text Add to dashboard Cite

show abstract

“…Seventeen studies were further excluded after full-text review, because they were animal studies (n = 1), not designed as diagnostic studies (n = 5), reported exosomal miR-122 expression rather than circulating miR-122 expression (n = 3), evaluated single nucleotide polymorphisms of miR-122 (n = 1), or reported diagnostic efficacies with no available data for miR-122 (n = 7). Finally, 13 studies were included [11][12][13][14][16][17][18][19][20][21][22][23][24].…”

Section: Studies Identified By Databasementioning

confidence: 99%

“…BioMed Research International [11-14, 17, 21, 23], three in Egypt [16,18,19], one in Vietnam [22], one in Italy [20], and one in Australia [24]. The characteristics of the control populations were mixed, with inclusion of healthy controls, participants with HBV or HCV infection, and patients with liver cirrhosis or dysplastic nodules.…”

Section: Study Characteristics and Quality Evaluationmentioning

confidence: 99%

“…However, due to the small number of studies included, they were unable to evaluate the efficacy of circulating miR-122 for discriminating HCC patients from various control patient populations [15]. Since the publication of their meta-analysis, several additional studies regarding the diagnostic efficacy of miR-122 for HCC have been published [16][17][18][19][20][21][22][23][24]. Therefore, we aimed to quantitatively evaluate the potential diagnostic performance of circulating miR-122 for HCC in an updated meta-analysis.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Circulating MicroRNA-122 for the Diagnosis of Hepatocellular Carcinoma: A Meta-Analysis

Zhao

Lin

et al. 2020

BioMed Research International

View full text Add to dashboard Cite

Background. Circulating microRNA-122 (miR-122) has been recognized as a marker of hepatocellular carcinoma (HCC). The current meta-analysis was performed to quantitatively evaluate the diagnostic performance of circulating miR-122 for HCC. Methods. Related studies that evaluated the diagnostic performance of circulating miR-122 determined from pathophysiological examination for HCC were obtained by systematic searches of the PubMed and Embase databases. A randomized fixed effects model was applied according to the heterogeneity among studies. The pooled sensitivity, specificity, and area under the summary receiver operating characteristic curve (AUC) were calculated to evaluate the diagnostic accuracy. Publication bias was detected by Deeks' funnel plot asymmetry test. Results. Thirteen studies providing data for 920 HCC patients and 1217 controls were included in the meta-analysis. The pooled sensitivities, specificities, and AUCs of serum miR-122 were 0.76, 0.75, and 0.82, respectively, for discriminating HCC patients from overall controls; 0.85, 0.83, and 0.91, respectively, for discriminating HCC patients from healthy controls; 0.79, 0.82, and 0.87, respectively, for discriminating HCC from HBV or HCV infection; and 0.65, 0.75, and 0.74, respectively, for discriminating HCC from liver cirrhosis or dysplastic nodule formation. No significant publication bias was detected. Conclusions. Serum miR-122 confers moderate efficacy for discriminating HCC patients from healthy controls or patients with HBV or HCV infection, but not for discriminating HCC patients from those with liver cirrhosis or dysplastic nodule formation.

show abstract

Advances in the early diagnosis of hepatocellular carcinoma

Wang¹,

Wei²

2020

Genes & Diseases

223

161

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is one of the most prevalent cancers globally. In contrast to the declining death rates observed for all other common cancers such as breast, lung, and prostate cancers, the death rates for HCC continue to increase by ~2–3% per year because HCC is frequently diagnosed late and there is no curative therapy for an advanced HCC. The early diagnosis of HCC is truly a big challenge. Over the past years, the early diagnosis of HCC has relied on surveillance with ultrasonography (US) and serological assessments of alpha-fetoprotein (AFP). However, the specificity and sensitivity of US/AFP is not satisfactory enough to detect early onset HCC. Recent technological advancements offer hope for early HCC diagnosis. Herein, we review the progress made in HCC diagnostics, with a focus on emerging imaging techniques and biomarkers for early disease diagnosis.

show abstract

Optimisation of quantitative miRNA panels to consolidate the diagnostic surveillance of HBV-related hepatocellular carcinoma

Cited by 16 publications

References 35 publications

Circulating microRNA‐1246 as a possible biomarker for early tumor recurrence of hepatocellular carcinoma

Circulating microRNA‐1246 as a possible biomarker for early tumor recurrence of hepatocellular carcinoma

Circulating MicroRNA-122 for the Diagnosis of Hepatocellular Carcinoma: A Meta-Analysis

Advances in the early diagnosis of hepatocellular carcinoma

Contact Info

Product

Resources

About